PharmiWeb.com - Global Pharma News & Resources
30-Nov-2018

Vasopressin Receptor Antagonist - Pipeline Insight Report 2018 Featuring Astellas, Bayer, Biovie, Azevan Pharmaceuticals, Ferring & Roche - ResearchAndMarkets.com

The "Vasopressin Receptor Antagonist - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Vasopressin Receptor Antagonist - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Vasopressin Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Vasopressin Receptor Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the report:

  • Provides a snapshot of the therapeutics pipeline activity for Vasopressin Receptor Antagonist
  • Features the Vasopressin Receptor Antagonist pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Vasopressin Receptor Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Vasopressin Receptor Antagonist

Key Topics Covered:

1. Report Introduction

2. Vasopressin Receptor Antagonist - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Vasopressin Receptor Antagonist

4. Comparative Analysis

5. Vasopressin Receptor Antagonist Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Vasopressin Receptor Antagonist Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Astellas
  • Bayer
  • Biovie
  • Azevan Pharmaceuticals
  • Ferring
  • Roche

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rx8rpx/vasopressin?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181130005404/en/

Editor Details

Last Updated: 30-Nov-2018